FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

IDEXX Laboratories, Inc. IDXX

Strong   Medical Devices & Diagnostics sector · IDEXX — veterinary diagnostics with a razor-and-blade instrument/consumable model.

IDEXX Laboratories, Inc. (IDXX) is an established Medical Devices & Diagnostics company, graded Strong on FrontierLab's evidence-based quality rubric (data as of 2026-08-21). Revenue grew 12.8% year-over-year at a 62.4% gross margin. Gross-profits-to-assets is 0.83; Rule of 40 is 44.8. Net share issuance -0.4% YoY (flat share count). No risk flags are currently noted. Analyst mix: 14 buy / 8 hold / 0 sell.

These sentences are generated from the day's data by deterministic templates.

Key quality signals

Revenue growth (YoY)12.8%
Gross margin62.4%
Gross profits / assets0.83
Rule of 4044.8
Net margin32%
Cash runway (months)
PEG2.2
Price / sales9.5

Quality checklist

Each line is one quality test behind the grade — passed · ~ borderline · failed. Hover a metric in the tables below for what it means.

Grade history

Graded Strong since 2026-06-17 — no grade changes recorded yet.

How have Strong-graded names performed?

The forward returns of all Strong-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.

WindowForward record vs the S&PMedian
~1 month59% of Strong-graded names beat the S&P over 21 sessions (95% CI 41–74%, N=29).Median excess vs the S&P was +4.2%.
~3 monthsbuilding — 13 more sessions needed
~6 monthsbuilding — 76 more sessions needed

Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →

How it compares

Revenue growth: lower than most Medical Devices & Diagnostics peers (N=7)
Gross profits / assets: higher than most Medical Devices & Diagnostics peers (N=7)
Gross margin: lower than most Medical Devices & Diagnostics peers (N=7)

Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.

Fundamentals

Market cap$43.06B
StageEstablished
Share issuance (YoY)-0.4% · flat share count
MoatWide
TAMLARGE
P/E (trailing)38.7
EPS (trailing)$14.12
Burn multiple
Gross-margin trend (pts)0.9
Cash / assets0.06
Accruals (%)-6.7%
Net debt / EBITDA0.6
Statements as ofQ2 FY2026 · filed 2026-08-04

Momentum context — describes the past, not a signal

52-week range
$518.55$769.98

Low reached Jun 30, 2026 · high reached Nov 25, 2025 — by daily close.

Price$545.86 (as of 2026-08-20)
Last session move
% off 52-wk high-29.1%
RSI (14)43
Relative volume0.9×

Analyst mix

Strong buy7
Buy7
Hold8
Sell0
Strong sell0

Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.

From the headlines

Execution solid but elevated valuation continues to weigh on stock.

AI take — daily, AI-generated

AI leans cautious

Solid business but the 2.2 PEG and 0.83 GP/A (highest here) signal you're overpaying; execution is there, but price isn't attractive.

Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.

Similar Medical Devices & Diagnostics names

Intuitive Surgical, Inc.Edwards Lifesciences CorporationInsulet Corp.Boston Scientific CorporationDexCom, Inc.Stryker Corporation

← All Medical Devices & Diagnostics names · Open IDXX in the interactive screener →

Data as of 2026-08-21 08:12 (end-of-day). How grades are computed →